Abstract
Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection of previously infected individuals, but the contribution of this process to variability in annual epidemics is not well understood. Here we link influenza A(H3N2) virus evolution to regional epidemic dynamics in the United States during 1997—2019. We integrate phenotypic measures of HA antigenic drift and sequence-based measures of HA and NA fitness to infer antigenic and genetic distances between viruses circulating in successive seasons. We estimate the magnitude, severity, timing, transmission rate, age-specific patterns, and subtype dominance of each regional outbreak and find that genetic distance based on broad sets of epitope sites is the strongest evolutionary predictor of A(H3N2) virus epidemiology. Increased HA and NA epitope distance between seasons correlates with larger, more intense epidemics, higher transmission, greater A(H3N2) subtype dominance, and a greater proportion of cases in adults relative to children, consistent with increased population susceptibility. Based on random forest models, A(H1N1) incidence impacts A(H3N2) epidemics to a greater extent than viral evolution, suggesting that subtype interference is a major driver of influenza A virus infection dynamics, presumably via heterosubtypic cross-immunity.
Impact statement: Antigenic drift in influenza’s major surface proteins – hemagglutinin and neuraminidase – contributes to variability in epidemic magnitude across seasons but is less influential than subtype interference in shaping annual outbreaks.
Competing Interest Statement
The WHO Collaborating Centre for Reference and Research on Influenza in Melbourne has a collaborative research and development agreement (CRADA) with CSL Seqirus for isolation of candidate vaccine viruses in cells and an agreement with IFPMA for isolation of candidate vaccine viruses in eggs. SGS reports honoraria from CSL Seqirus, Moderna, Pfizer, and Evo Health. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines, SARS-CoV-2 serological assays, and SARS-CoV-2 vaccines which list FK as co-inventor. Mount Sinai has spun out companies, Kantaro and Castlevax, to market the SARS-CoV-2 related technologies. FK has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures, GSK and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2 and with Dynavax on universal influenza virus vaccines. All other authors declare no competing interests.
Funding Statement
ACP, CLH, and CV were supported by the in-house research division of the Fogarty International Center, US National Institutes of Health. ACP was supported by the NSF Infectious Disease Evolution Across Scales (IDEAS) Research Collaboration Network. JH was supported by NIH NIAID awards F31 AI140714 and R01 AI165821. The work done at the Crick Worldwide Influenza Centre was supported by the Francis Crick Institute receiving core funding from Cancer Research UK (FC001030), the Medical Research Council (FC001030) and the Wellcome Trust (FC001030). SF, KN, NK, SW and HH were supported by the Ministry of Health, Labour and Welfare, Japan (10110400 and 10111800). SW was supported by the Japan Agency for Medical Research and Development (JP22fk0108118 and JP23fk0108662). The WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australia Government Department of Health and Aged Care. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. Influenza virus work in the Krammer laboratory was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C, NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 (FK), and NIAID CIVIC contract (75N93019C00051). TB was supported by NIH awards NIGMS R35 GM119774 and NIAID R01 AI127893. TB is an Investigator of the Howard Hughes Medical Institute. Funding sources were not involved in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The human surveillance data and viral sequence data used in this study are anonymous and were openly available to the public prior to the initiation of this study. Influenza syndromic and virologic surveillance data can be obtained from the US Centers for Disease Control and Prevention (CDC) FluView Interactive dashboard (https://www.cdc.gov/flu/weekly/fluviewinteractive.htm). Influenza viral sequence data can be obtained from the Global Initiative on Sharing All Influenza Data (GISAID) database (https://gisaid.org/). The GISAID Initiative ensures that open access to data in GISAID is provided free-of-charge to all individuals that agreed to identify themselves and agreed to uphold the GISAID sharing mechanism governed through its Database Access Agreement.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This article is now a "reviewed preprint" at eLife (https://doi.org/10.7554/eLife.91849.1) and has been updated to incorporate peer reviewer feedback. In this revised manuscript, we expand on the potential drivers and biological implications of some of our findings, explicitly note the diversification of A(H3N2) viruses during the 2010s, and provide more justification and clarification of our methodology.
Data Availability
Sequence data are available from GISAID using accession ids provided in Supplementary file 1. Source code for phylogenetic analyses, inferred HI titers from serological measurements, and evolutionary fitness measurements are available in the GitHub repository https://github.com/blab/perofsky-ili-antigenicity. The five replicate trees for HA and NA can be found at https://nextstrain.org/groups/blab/ under the keyword 'perofsky-ili-antigenicity'. Epidemiological data, datasets combining seasonal evolutionary fitness measurements and epidemic metrics, and source code for calculating epidemic metrics and performing statistical analyses are available at https://doi.org/10.5281/zenodo.11188848 and https://github.com/aperofsky/H3N2_Antigenic_Epi. Raw serological measurements are restricted from public distribution by previous data sharing agreements.
https://github.com/blab/perofsky-ili-antigenicity
https://nextstrain.org/groups/blab/
